

BJPpsych

The British Journal of Psychiatry



Developmental pathways from childhood conduct problems to early adult depression: findings from the ALSPAC cohort

Argyris Stringaris *et al*

Relationship between obesity and the risk of clinically significant depression: Mendelian randomisation study

Chi-Fa Hung *et al*

Comparative mortality risks of antipsychotic medications in community-dwelling older adults

Tobias Gerhard *et al*

Activity and views of service users involved in mental health research: UK survey

Sue Patterson *et al*

- A1 Editorial Board
A3 Highlights of this issue

Editorials

- 1 **A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)**
O. D. Howes and S. Kapur

- 3 **Stages of Mental Illness – psychiatry in pictures**
Lesley Harper

- 4 **Prescription of antipsychotics in people with dementia**
C. Ballard, A. Corbett and R. Howard

- 6 **Use of medication for challenging behaviour in people with intellectual disability**
G. Glover, S. Bernard, D. Branford, A. Holland and A. Strydom

Review article

- 8 **Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis**
D. M. Pearlman, H. S. Vora, B. G. Marquis, S. Najjar and L. A. Dudley

- 16 **The Man with the Wooden Leg – poem**
Katherine Mansfield

- 44 **Comparative mortality risks of antipsychotic medications in community-dwelling older adults**

T. Gerhard, K. Huybrechts, M. Olfson, S. Schneeweiss, W. V. Bobo, P. M. Doraiswamy, D. P. Devanand, J. A. Lucas, C. Huang, E. S. Malka, R. Levin and S. Crystal

- 52 **Effects of a mindfulness-based psychoeducation programme for Chinese patients with schizophrenia: 2-year follow-up**
W. T. Chien and D. R. Thompson

- 60 **Insight, duration of untreated psychosis and attachment in first-episode psychosis: prospective study of psychiatric recovery over 12-month follow-up**
A. I. Gumley, M. Schwannauer, A. Macbeth, R. Fisher, S. Clark, L. Rattrie, G. Fraser, R. McCabe, A. Blair, K. Davidson and M. Birchwood

- 68 **Activity and views of service users involved in mental health research: UK survey**
S. Patterson, J. Trite and T. Weaver

Columns

- 76 Correspondence
79 Contents of *Advances in Psychiatric Treatment*
80 Book review
81 Contents of the *American Journal of Psychiatry*
82 From the Editor's desk

Papers

- 17 **Developmental pathways from childhood conduct problems to early adult depression: findings from the ALSPAC cohort**
A. Stringaris, G. Lewis and B. Maughan
- 24 **Relationship between obesity and the risk of clinically significant depression: Mendelian randomisation study**
C.-F. Hung, M. Rivera, N. Craddock, M. J. Owen, M. Gill, A. Korszun, W. Maier, O. Mors, M. Preisig, J. P. Rice, M. Rietschel, L. Jones, L. Middleton, K. J. Aitchison, O. S. P. Davis, G. Breen, C. Lewis, A. Farmer and P. McGuffin
- 29 **Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study**
Z. Li, C. Zhang, J. Fan, C. Yuan, J. Huang, J. Chen, Z. Yi, Z. Wang, W. Hong, Y. Wang, W. Lu, Y. Guan, Z. Wu, Y. Su, L. Cao, Y. Hu, Y. Hao, M. Liu, S. Yu, D. Cui, L. Xu, Y. Song and Y. Fang
- 36 **Impact of depressive episodes on cognitive deficits in early bipolar disorder: data from the Systematic Treatment Optimization Programme for Early Mania (STOP-EM)**
K. Muralidharan, I. J. Torres, L. E. Silveira, J.-M. Kozicky, J. Bucker, N. Fernando and L. N. Yatham

- 43 **Randomised controlled trials – in 100 words**
John Geddes

Cover picture

Sean in Blue (May 2012). Alexandra Long (b. 1988)

I am currently an FY1 doctor and previously worked within an acute in-patient psychiatric unit for working-age adults. As doctors, we face decisions that determine a patient's future quality of life and mortality, as well as dealing with the pressures of frequent examinations on our journey to consultancy. It is no wonder then that many doctors fall victim to work-related anxiety. I created this portrait to exemplify the isolation, intensity and severe stress that can typify this anxiety. I hope that in portraying psychiatric symptoms that many clinicians can relate to, the viewer is able to empathise more fully with the entire spectrum of mental health – from eccentricities and transient anxiety they may identify in their own lives, through to pathological symptoms. Perhaps if clinicians, both within and outside the field of psychiatry, could better identify these traits in themselves, they might also begin to consider their own patients' journeys and symptoms with more insight.



We are always looking for interesting and visually appealing images for the cover of the *Journal* and would welcome suggestions or pictures, which should be sent to Dr Allan Beveridge, British Journal of Psychiatry, 21 Prescott Street, London E1 8BB, UK or bjp@rcpsych.ac.uk.

Highlights of this issue

By Sukhwinder S. Shergill

Antipsychotic medication in the elderly

Dementia commonly presents comorbid behavioural and psychological disturbance, which cause significant distress to the patient and carers alike, and are challenging to manage effectively. The most frequently reported symptoms are psychosis, aggression or agitation. There has been a widespread awareness of the increased risk of mortality related to treatment of these symptoms with antipsychotic medication. Gerhard *et al* (pp. 44–51) examined the mortality risk associated with new initiation of six different antipsychotic medications in community-based patients aged over 65 years, with and without a diagnosis of dementia. They found that many antipsychotics – including haloperidol, risperidone and olanzapine – demonstrated a positive dose–response effect. The authors advocate a cautious and targeted approach when using antipsychotic medication in this vulnerable population. They suggest that particular attention needs to be paid to using the lowest possible dose of antipsychotic, especially with haloperidol. An accompanying editorial by Ballard and colleagues (pp. 4–5) reviews the background literature in relation to dementia; they highlight the association of higher doses of antipsychotic medication with greater risk of mortality – independent of a diagnosis of dementia – and confirm the value of using the lowest possible effective doses of antipsychotics and using haloperidol with great caution.

Psychosis, mindfulness, insight and resistance to treatment

Psychoeducation for patients with schizophrenia has been shown to improve their outcomes in some studies; similarly, the use of mindfulness-based stress reduction programmes has demonstrated a beneficial reappraisal of their illness. Chien & Thompson (pp. 52–59) report the result of a randomised controlled 6-month trial of mindfulness in schizophrenia, which resulted in improvements in symptom severity, function and insight. The authors, based in China, suggest that their mindfulness-based treatment programme offered an effective community-based intervention for schizophrenia. The role of attachment style in influencing the process of symptomatic recovery was examined in a prospective study of patients with first-episode psychosis in Scotland. Gumley *et al* (pp. 60–67) report that almost 70% of patients showed an insecure attachment; this did not predict change in positive symptoms but was a predictor of greater intensity of negative symptoms. They advocate an integration of interpersonal and metacognitive psychological therapies in order to facilitate better adaption to emotionally laden interpersonal events. Classification in psychiatry has been in the public eye with the recent publication

of DSM-5; Howes & Kapur (pp. 1–3) revisit the diagnosis of schizophrenia in an editorial that highlights the value of using treatment response as a neurobiological marker of different neurochemical mechanisms operating in schizophrenia. They suggest that treatment-refractory schizophrenia may be a different type of illness, related to abnormalities in other neurotransmitter systems, such as glutamate, as opposed to the more conventional type of illness that is modelled by dopaminergic hyper-responsivity and treated with current dopamine-modulating antipsychotic medication.

Depression, cognitive deficits and brain-derived neurotrophic factor

While depression is common and recognised to be a multifactorial illness, the impact of early childhood conduct disorder on developing subsequent depressive illness remains uncertain. Stringaris and colleagues (pp. 17–23) use longitudinal data to demonstrate that early-life conduct difficulties were significantly associated with later development of depressive disorder. They suggest that this may offer an opportunity for early intervention, warranting both a careful assessment for depression during early-stage conduct disorder and interventions aimed at treating depression, in addition to the behavioural disorder, at this early stage. The impact of depressive episodes on the development of cognitive deficits in bipolar disorder is not clear; the report of Muralidharan *et al* (pp. 36–43) found that depressive episodes did not contribute any specific cognitive deficits, beyond the broad range of deficits associated with bipolar disorder generally. However, they noted that poorer verbal memory may serve as a marker for depressive recurrence in bipolar disorder. Brain-derived neurotrophic factor (BDNF) affects brain development and connectivity, and occurs at lower levels in bipolar disorder. Li and colleagues (pp. 29–35) examined a prospective cohort of patients with a first episode of depressive illness to assess the impact of BDNF levels on developing a bipolar illness. They found that the combination of BDNF gene expression and plasma BDNF offered the best predictor of those people at greater risk of developing subsequent bipolar disorder.

Service user involvement in research

It's clear that involving service users in mental health-related research has several advantages, including the addition of a highly relevant perspective to the research process; however, systematic data on the people involved and their experience of the process have not been well explored. Patterson and colleagues (pp. 68–75) found that there is a diverse and highly skilled service user body contributing to mental health research. However, they did comment on concerns raised by service users that their involvement was sometimes treated as tokenism, with some of them reporting feelings of stigmatisation and discrimination. Overall, service users reported their involvement in research as a positive experience.